US09090D1037 - Common Stock - After market: 0.3799 0 (0%)
NYSEARCA:PHGE (2/3/2023, 7:04:01 PM)0 (-0.96%)
|GICS Sector||Health Care|
|Earnings (Last)||11-09 2022-11-09/bmo||Earnings (Next)||05-09 2023-05-09/amc|
|Ins Owners||N/A||Inst Owners||20.55%|
Find more stocks on American Stock Exchange
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
BiomX, Inc. operates as a clinical-stage microbiome company. The firm is focused on developing both natural and engineered phage therapies. The company develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The firm discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
22 Einstein St., Floor 5
Ness Ziona 7414002
CEO: Jonathan Solomon
It's the final day of trading this week and we're checking in on the biggest pre-market stock movers for Friday morning!
NESS ZIONA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company...
Continued Progress Enrolling Patients in Phase 1/2 Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis; Results from Part 1 of the Trial Now...
NESS ZIONA, Israel, Nov. 02, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company...
Good morning, investor! We're starting off Thursday with a breakdown of the biggest pre-market stock movers this morning!
Good morning! We're taking a look at the biggest pre-market stock movers traders need to know about on Thursday morning!
Here you can normally see the latest stock twits on PHGE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.